Pre‐Treatment Biomarkers Associated With Remission of Type 2 Diabetes in Response to Short‐Term Insulin‐Based Therapy

ABSTRACT Aims Short‐term insulin‐based therapy can induce remission of Type 2 diabetes (T2DM) in some but not all patients. The underlying determinant of whether remission can be achieved is beta‐cell function, but its assessment typically requires complex challenge testing. We thus sought to determine if there exist circulating biomarkers associated with the likelihood of achieving remission prior to initiating short‐term insulin‐based therapy, without requiring challenge testing. Methods Adults with T2DM of ≤ 7 years duration were randomized to 8 weeks treatment with (i) insulin glargine, (ii) glargine + thrice‐daily lispro or (iii) glargine + twice‐daily exenatide, followed by 12 weeks washout that enabled assessment for remission (A1c < 6.5% after ≥ 3 months without glucose‐lowering therapy). We assessed the following fasting biomarkers at baseline in relation to subsequent remission: fibroblast growth factor‐21 (FGF‐21), C‐reactive protein (CRP), vascular cell adhesion molecule‐1 (VCAM‐1), interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), interleukin‐4 (IL‐4), monocyte chemoattractant protein‐1 (MCP‐1) and dipeptidyl peptidase‐4 (DPP‐4). Results Remission occurred in 31 of 90 participants (34.4%). At baseline, compared to their non‐remitting peers, those in whom remission was subsequently achieved had higher Homeostasis Model Assessment of beta‐cell function (HOMA‐B; p = 0.02), lower fasting proinsulin: C‐peptide ratio ( p = 0.008) and borderline higher prevalence of detectable IL‐4 ( p = 0.06), though significance did not persist after multiplicity‐adjustment. On exploratory logistic regression analyses, baseline detectable IL‐4 (aOR = 3.58; 95% CI: 1.25–10.99) and HOMA‐B (aOR = 1.77; 95% CI: 1.11–2.99) were associated with remission. Conclusion Prior to treatment, higher HOMA‐B and detectable IL‐4 are candidate markers warranting further study for association with subsequent remission of T2DM in response to short‐term insulin‐based therapy.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-15
DOI
https://doi.org/10.1111/dom.71551
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre‐Treatment Biomarkers Associated With Remission of Type 2 Diabetes in Response to Short‐Term Insulin‐Based Therapy

Junwei Shen, Jacqueline Leah Beaudry, Mihir Parikh, Ravi R. Retnakaran et al.
Diabetes Obesity and Metabolism
Diabetes Treatment and Management
article

Pre‐Treatment Biomarkers Associated With Remission of Type 2 Diabetes in Response to Short‐Term Insulin‐Based Therapy

Junwei Shen, Jacqueline Leah Beaudry, Mihir Parikh, Ravi R. Retnakaran, Bernard Zinman, KURINCHE THIYAGARAJAH
article en

Abstract

ABSTRACT Aims Short‐term insulin‐based therapy can induce remission of Type 2 diabetes (T2DM) in some but not all patients. The underlying determinant of whether remission can be achieved is beta‐cell function, but its assessment typically requires complex challenge testing. We thus sought to determine if there exist circulating biomarkers associated with the likelihood of achieving remission prior to initiating short‐term insulin‐based therapy, without requiring challenge testing. Methods Adults with T2DM of ≤ 7 years duration were randomized to 8 weeks treatment with (i) insulin glargine, (ii) glargine + thrice‐daily lispro or (iii) glargine + twice‐daily exenatide, followed by 12 weeks washout that enabled assessment for remission (A1c < 6.5% after ≥ 3 months without glucose‐lowering therapy). We assessed the following fasting biomarkers at baseline in relation to subsequent remission: fibroblast growth factor‐21 (FGF‐21), C‐reactive protein (CRP), vascular cell adhesion molecule‐1 (VCAM‐1), interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), interleukin‐4 (IL‐4), monocyte chemoattractant protein‐1 (MCP‐1) and dipeptidyl peptidase‐4 (DPP‐4). Results Remission occurred in 31 of 90 participants (34.4%). At baseline, compared to their non‐remitting peers, those in whom remission was subsequently achieved had higher Homeostasis Model Assessment of beta‐cell function (HOMA‐B; p = 0.02), lower fasting proinsulin: C‐peptide ratio ( p = 0.008) and borderline higher prevalence of detectable IL‐4 ( p = 0.06), though significance did not persist after multiplicity‐adjustment. On exploratory logistic regression analyses, baseline detectable IL‐4 (aOR = 3.58; 95% CI: 1.25–10.99) and HOMA‐B (aOR = 1.77; 95% CI: 1.11–2.99) were associated with remission. Conclusion Prior to treatment, higher HOMA‐B and detectable IL‐4 are candidate markers warranting further study for association with subsequent remission of T2DM in response to short‐term insulin‐based therapy.

Diabetes Obesity and Metabolism
Mount Sinai Hospital (CA), University of Toronto (CA), Lunenfeld-Tanenbaum Research Institute (CA)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon